NCT06717815

Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

CompletedPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2025-02-25Est. Completion: 2026-06-08

Enrollment target: 24 participants

Locations

The First Affiliated Hospital Of Anhui Medical University, Hefei, Anhui, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Fujian Provincial Hospital, Fuzhou, Fujian, China
Sun Yai-sen Memorial Hospital, Sun Yai-sen University, Guangzhou, Guandong, China
Hebei Petro China Central Hospital, Langfang, Hebei, China
Xinxiang Central Hospital, Xinxiang, Henan, China
Renmin Hospital of Wuhan University, Wuhan, Hubei, China
Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, Hubei, China
Xiangya Hospital of Central South University, Changsha, Hunan, China
Nanjing DrumTower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Nantong First People's Hospital, Nantong, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Shandong Provincial Hospital, Jinan, Shandong, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, China

Lupus Nephritis (LN)Systemic Lupus Erythematosus (SLE)Autoimmune Diseases

This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of autologous ant…

Multiple LocationsEst. completion Dec 31, 2028

Lupus Erythematosus, Systemic

This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell thera…

San Francisco, United StatesEst. completion May 1, 2029

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.